References
- Canagliflozin (Invokana) Patient Package Insert (PPI). December 2015. https://www.invokanahcp.com/sites/www.invokanahcp.com/files/prescribing-information-invokana.pdf [Last accessed March 2016]
- American Diabetes Association. Section 7. Approaches to glycemic treatment. Standards of Medical Care in Diabetes – 2016. Diabetes Care 2016;39(Suppl1):S52-S9
- Handelsman Y, Bloomgarden ZT, Grunberger G, et al. American Association of Clinical Endocrinologists and American College of Endocrinology Clinical Practice Guidelines for Developing a Diabetes Mellitus Comprehensive Care Plan – 2015. Endocrine Practice 2015;21(Suppl1):1-87
- Rosenstock J, Aggarwal N, Polidori D, et al. Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes. Diabetes Care 2012;35:1232-8
- Schernthaner G, Gross JL, Rosenstock J, et al. Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea. Diabetes Care 2013;36:2508-15
- Cefalu WT, Leiter LA, Yoon K-H, et al. Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomized, double-blind, phase 3 non-inferiority trial. Lancet 2013;382:941-50
- Neal B, Perkovic V, de Zeeuw D, et al. Efficacy and safety of canagliflozin, an inhibitor of sodium-glucose cotransporter 2, when used in conjunction with insulin therapy in patients with type 2 diabetes. Diabetes Care 2015;38:403-11
- Neal B, Perkovic V, de Zeeuw D, et al. Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS) – a randomized placebo-controlled trial. Am Heart J 2013;166:217-23.e11
- Fulcher G, Matthews DR, Perkovic V, et al. Efficacy and safety of canagliflozin when used in conjunction with incretin-mimetic therapy in patients with type 2 diabetes. Diab Obes Metab 2016;18:82-91
- Lavalle-Gonzalez FJ, Januszewicz J, Davidson J, et al. Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial. Diabetologia 2013;56:2582-92
- Buysman EK, Chow W, Henk HJ, et al. Characteristics and short-term outcomes of patients with type 2 diabetes mellitus treated with canagliflozin in a real-world setting. Curr Med Res Opin 2015;31:137-43
- Meckley LM, Miyasato G, Kokkotos F, et al. An observational study of glycemic control in canagliflozin treated patients. Curr Med Res Opin 2015;31:1479-86
- Buysman EK, Chow W, Henk HJ, et al. Characteristics and outcomes of patients with type 2 diabetes mellitus treated with canagliflozin: a real-world analysis. BMC Endocr Disord 2015;15:67
- Thayer S, Chow W, Korrer S, et al. Real-world evaluation of glycemic control among patients with type 2 diabetes mellitus treated with canagliflozin versus dipeptidyl peptidase-4 inhibitors. Curr Med Res Opin 2016: published online 16 March 2016: 1-10 DOI: 10.1185/03007995.2016.1159954
- Lefebvre P, Pilon D, Robitaille MN, et al. Real-world glycemic, blood pressure, and weight control in patients with type 2 diabetes mellitus treated with canagliflozin-an electronic health-record-based study. Curr Med Res Opin 2016: published online 11 May 2016: 1-9 DOI: 10.1080/03007995.2016.1183604